anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Age-related hearing loss is a risk factor for mobility problems and falls, possibly due to poor access to spatial sounds or the higher allocation of attention required to listen, thereby reducing cognitive resources to support mobility. Introducing stabilizing spatial sounds or reducing cognitive load through hearing aids could possibly improve balance performance; however, evidence is mixed. Few studies have evaluated the effects of hearing aids and spatial sounds on balance during realistic, multisensory, dual-tasking conditions. This study used virtual reality to simulate a listening-while-balancing task in 22 older adults with normal hearing and 22 hearing aid users, tested with their aids on versus off. Participants performed a competing digits listening task (two, four digits) and a standing postural task, alone and in combination (dual task) under different visual, postural, and acoustical loads. Listening accuracy and postural outcomes (centre of pressure mean velocity, anterior-posterior standard deviation, medial-lateral standard deviation) were collected. With respect to listening accuracy, as expected, normal hearing adults had higher listening accuracy than those with hearing loss (aided better than unaided) and both groups performed better with eyes closed (vs. open) and under lower postural loads (firm vs. compliant). With respect to postural performance, hearing aids did not remarkably improve balance overall, with no effects on dual-task costs to posture. Other factors related to the complexity of the conditions (i.e., listening, visual, postural demands) differently influenced dual-task costs to posture in individuals with and without hearing loss. Overall, these results contribute to our understanding of how age-related hearing loss and hearing aids affect balance-related outcomes under realistic, complex, multisensory, multitasking conditions.
OBJECTIVES: I. Compare the response rate, response duration, time to response, time to progression, and survival of patients with relapsed limited or extensive stage small cell lung cancer treated with oral vs intravenous topotecan. II. Compare the qualitative and quantitative toxicities of these treatment regimens in this patient population. III. Compare the quality of life in these patients.

OUTLINE: This is randomized, multicenter study. Patients are stratified according to gender, liver metastases (yes vs no), and duration of response to prior chemotherapy (6 months or less vs greater than 6 months). Patients are randomized to one of two treatment arms. Arm I: Patients receive topotecan IV over 30 minutes on days 1-5. Arm II: Patients receive topotecan orally on days 1-5. Treatment repeats every 3 weeks in the absence of unacceptable toxicity. Patients experiencing complete or partial response continue until progression or for at least 2 courses past maximal response. Patients with stable disease should receive at least 4 courses. Quality of life is assessed Patients are followed every 3 months.

PROJECTED ACCRUAL: A total of 300 patients (150 per treatment arm) will be accrued for this study.
NEW MATERIAL:A compound shown by the formula I (R<1> is H, lower alkyl, lower alkenyl, phenyl lower alkyl, or lower alkynyl; R<2> is cycloalkyl, or phenyl which may contain 1-3C group selected from halogen, lower alkyl and lower alkoxy as substituent group on phenyl ring, etc.) and its salt. EXAMPLE:2-Benzamido-3-(oxindol-3-yl)propionic acid. USE:An antiulcer. Having improved preventing and remedying effect especially chronic exulcerans state such as ulcer of acetic acid of experiment, ulcer of thermocautery, etc. Having low toxicity and side effects, a drug effective against chronic ulcer. PREPARATION:A compound shown by the formula II is subjected to a common reaction of amide bond formation with a carboxylic acid shown by the formula R<2>COOH, to give a compound shown by the formula I .
CSF-venous fistulas (CVFs) are increasingly recognised as a cause of spontaneous intracranial hypotension. They may present atypically including with brain sagging pseudo-dementia. Cervical CVFs are rare and their management can be difficult due to associated eloquent nerve roots. We report the case of a 49-year-old woman who presented with cognitive decline progressing to coma. Brain imaging showed features of spontaneous intracranial hypotension and a right C7 CVF was identified at digital subtraction and CT myelography. Initial treatment with CT-guided injection of fibrin sealant produced temporary improvement in symptoms before surgical treatment resulted in total clinical remission and radiological resolution.
It has been reported that postoperative vision loss after lumbar surgery is increasing. It is an uncommon but devastating complication. One of the risk factors that has been reported is increased intraocular pressure (IOP), which may decrease perfusion pressure to the optic nerve. Intraocular pressure in anesthetized, prone spine patients has been studied with the head in neutral position. The prone position and duration of the procedure did increase the IOP. Our hypothesis is that adjusting the position of the head in space will alter the intraocular pressure, with an extended position decreasing IOP. This study is a, randomized, controlled design: neutral head position (standard care) or extended head position (intervention group). Patients who qualify for spinal fusion surgery and meet the inclusion criteria will be randomized to either the neutral (standard practice) or the intervention group.Randomization of patients will be computer generated.
The present invention relates to a pharmaceutical composition comprising a cyclotide and a ligand of the kappa opioid receptor (the kOR), or a combination thereof, for use in treating Multiple Sclerosis (MS), in remyelination, in improving CNS lesions, in preventing or reducing demyelination and/or CNS lesions, and/or in treating pain, in particular neuropathic pain and/or pain resulting from/coming along with MS. The present invention further relates to a combination of a cyclotide and a ligand of the kOR and to a pharmaceutical composition comprising said combination. The present invention further relates to a use of a cyclotide for reducing adverse effects of a ligand of the kOR and/or for increasing the potency and/or efficacy of a ligand of the kOR. Further, the present invention relates to a kit comprising a cyclotide and a ligand of the kOR. The present invention further relates to a pharmaceutical composition as part of a kit, wherein a comprised cyclotide and ligand of the kOR are for use in treating MS and related diseases and/or symptoms. The present invention further relates to a kit comprising a pharmaceutical composition comprising a cyclotide and a ligand of the kOR, wherein said pharmaceutical composition and/or said cyclotide and ligand of the kOR is/are for use in treating MS and related diseases and/or symptoms. The invention further relates to (a) novel  Viola -type cyclotide(s).
OBJECTIVE: To determine work participation, social roles, and empowerment of QFS patients ≥10-year after infection.
METHODS: QFS patients ≥10-year after acute infection, who were of working age, participated in a cross-sectional survey study. Work participation, fulfilment of social roles, and empowerment outcomes were studied for the total population, as well as for subgroups based on employment type and current work status. Associations between empowerment, work and social roles were examined.
RESULTS: 291 participants were included. Of the 250 participants who had paid work before Q-fever, 80.4% stopped working or worked less hours due to QFS. For each social role, more than half of the participants (56.6-87.8%) spent less time on the role compared to before Q-fever. The median empowerment score was 41.0 (IQR: 37.0-44.0) out of 60. A higher empowerment score was significantly associated with lower odds of performing all social roles less due to QFS (OR = 0.871-0.933; p<0.001-0.026), except for parenting and informal care provision (p = 0.070-0.460). No associations were found between empowerment and current work status.
CONCLUSION: Work participation and fulfilment of social roles is generally low in QFS patients. Many of the participants stopped working or are working less hours due to QFS, and most spent less time on social roles compared to before Q-fever. Minor variation was seen in total empowerment scores of participants; however, these slight differences were associated with the fulfilment of social roles, but not work participation. This new insight should be further explored in future studies.
The group of school-aged children from Senegal who are being screened. Children will receive a single standard dose of benzimidazole drug (either 400mg of Albendazole or 500mg of Mebendazole) and stool samples will be collected prior to and 2-3 weeks following treatment.
Osteoarthritis (OA) is the most common form of musculoskeletal disease, and its prevalence is increasing due to the aging of the population. Chronic pain is the most burdensome symptom of OA that significantly lowers patients' quality of life, also due to its frequent association with emotional comorbidities, such as anxiety and depression. In recent years, both chronic pain and mood alterations have been linked to the development of neuroinflammation in the peripheral nervous system, spinal cord and supraspinal brain areas. Thus, mechanisms at the basis of the development of the neuroinflammatory process may indicate promising targets for novel treatment for pain and affective comorbidities that accompany OA. In order to assess the key role of neuroinflammation in the maintenance of chronic pain and its potential involvement in development of psychiatric components, the monoiodoacetate (MIA) model of OA in rodents has been used and validated. In the present commentary article, we aim to summarize up-to-date results achieved in this experimental model of OA, focusing on glia activation and cytokine production in the sciatic nerve, dorsal root ganglia (DRGs), spinal cord and brain areas. The association of a neuroinflammatory state with the development of pain and anxiety- and depression-like behaviors are discussed. Results suggest that cells and molecules involved in neuroinflammation may represent novel targets for innovative pharmacological treatments of OA pain and mood comorbidities.
Ischemia/reperfusion (I/R) injury is one of the major causes of cardiovascular disease. Gypenoside A (GP), the main active component of Gynostemma pentaphyllum, alleviates myocardial I/R injury. Circular RNAs (circRNAs) and microRNAs (miRNAs) are involved in the I/R injury. We explored the protective effect of GP on human cardiomyocytes (HCMs) via the circ_0010729/miR-370-3p/RUNX1 axis. Overexpression of circ_0010729 abolished the effects of GP on HMC, such as suppression of apoptosis and increase in cell viability and proliferation. Overexpression of miR-370-3p reversed the effect of circ_0010729 overexpression, resulting in the stimulation of HMC viability and proliferation and inhibition of apoptosis. The knockdown of miR-370-3p suppressed the effects of GP in HCMs. RUNX1 silencing counteracted the effect of miR-370-3p knockdown and maintained GP-induced suppression of apoptosis and stimulation of HMC viability and proliferation. The levels of RUNX1 mRNA and protein were reduced in cells expressing miR-370-3p. In conclusion, this study confirmed that GP alleviated the I/R injury of myocardial cell via the circ_0010729/miR-370-3p/RUNX1 axis.
The present invention relates to the treatment of T- helper type 2 (Th2)-mediated disease. Here, the inventors set out to investigate at the genome level the effects of SETDB1-dependent H3K9me3 deposition on CD4 T cell activation, differentiation and commitment. By using conditional Setdb1-/- mice, they show that SETDB1 restricts Th1 cell priming and ensures Th2 cell integrity. Unlike their wild-type counterparts, SETDB1-deficient Th2 cells readily express the entire Th1 gene network when exposed to the Th1-instructing cytokine IL-12. More, SETDB1 methylates H3K9 at a subset of ERVs that flank and repress Th1 enhancers or behave themselves as cis-regulatory elements of a large network of Th1 genes, including Ifng, Stat4, Runx3 and Tbx21. Therefore, H3K9me3 deposition by SETDB1 locks the Th1 gene expression program and thus ensures T cell lineage integrity by repressing a repertoire of ERVs that have been co-opted to behave as Th1 lineage-specific cis-regulatory modules. Thus, the invention relates to a SETDB1 inhibitor for use in a method for increasing the Th1/Th2 ratio of an immune response in a subject in need thereof.
Mechanical ventilation (MV) is an essential therapy for acute respiratory distress syndrome (ARDS) and pulmonary fibrosis. However, it can also induce mechanical ventilation-induced pulmonary fibrosis (MVPF) and the underlying mechanism remains unknown. Based on a mouse model of MVPF, the present study aimed to explore the role of the angiotensin-converting enzyme/angiotensin II/angiotensin type 1 receptor (ACE/Ang-2/AT1R) axis in the process of MVPF. In addition, recombinant angiotensin-converting enzyme 2(rACE2), AT1R inhibitor valsartan, AGTR1-directed shRNA and ACE inhibitor perindopril were applied to verify the effect of inhibiting ACE/Ang-2/AT1R axis in the treatment of MVPF. Our study found MV induced an inflammatory reaction and collagen deposition in mouse lung tissue accompanied by the activation of ACE in lung tissue, increased concentration of Ang-2 in bronchoalveolar lavage fluid (BALF), and upregulation of AT1R in alveolar epithelial cells. The process of pulmonary fibrosis could be alleviated by the application of the ACE inhibitor perindopril, ATIR inhibitor valsartan and AGTR1-directed shRNA. Meanwhile, rACE2 could also alleviate MVPF through the degradation of Ang-2. Our finding indicated the ACE/Ang-2/AT1R axis played an essential role in the pathogenesis of MVPF. Pharmacological inhibition of the ACE/Ang-2/AT1R axis might be a promising strategy for the treatment of MVPF.
OBJECTIVE: Routine evaluation and surveillance imaging after pituitary adenoma (PA) endoscopic endonasal transsphenoidal resection (EETS) is a neurosurgical practice to identify tumor recurrence. This study aims to identify social and clinical factors that may contribute to patients missing their initial 1-year follow-up appointment and provide guidance for targeted education to improve patient adherence with postoperative treatment plans, ultimately reducing unknown adenoma recurrence.
METHODS: The authors performed a single-center retrospective review of patients who underwent EETS for PAs from 2007 to 2023. Patients were analyzed for sociodemographic factors, presenting symptoms, time to surgery, surgical outcomes, and adherence to postoperative follow-up visits at 1 year after surgery.
RESULTS: A total of 256 patients with PAs treated by EETS met inclusion criteria; 218 (85%) of these patients attended 1-year follow-up, and 38 (15%) missed this visit. Twenty-nine (76%) individuals who missed their 1-year follow up were men (P = 0.006). Divorced/widowed/separated patients were 2 times more likely to miss their follow-up compared with their married counterparts (P = 0.008). Additional significant risk factors included older age, as the mean age for patients who missed their 1-year appointment was 60.1 years compared with 54.7 years (P = 0.028). Patients with visual field deficits at initial presentation were also less likely to follow-up at 1 year (P = 0.03).
CONCLUSIONS: Risk factors of missed 1-year follow-up appointments after PA resection include male sex, divorced/widowed/separated marital status, older age, and the presence of visual deficits at initial presentation. Increased education efforts can be selectively aimed at these at-risk patient cohorts to improve patient compliance and reduce consequences of undetected tumor recurrence.
OBJECTIVE: The purpose of this study was to evaluate the additional contribution of the Mitrofanoff channel to health-related quality of life (HRQoL).
METHODS: Between 2005 and 2009, we conducted a retrospective study on 10 pediatric patients who underwent Mitrofanoff surgery for neurogenic bladder and 11 control patients using urethral catheterization. We evaluated HRQoL using questionnaires tailored for various age groups, with higher scores indicating better QoL.
RESULTS: The mean age in the patient group was 12.8 years and 10.7 years in the control group (p = 0.103). Shunt use and wheelchair dependency were similar between groups (p = 0.217 and p = 0.505, respectively). Diaper use showed no significant difference (p = 0.256). Notably, 50% of the patient group performed self-catheterization compared to 9.1% in the control group, a significant difference (p = 0.038). Prophylaxis application was significantly higher in the control group (p = 0.049). HRQoL scores were not significantly different between surgery and control groups in children (p = 0.251) and adolescents (p = 0.831), with Cronbach's α values indicating high reliability of the HRQoL scale.
CONCLUSIONS: Although the procedure shows potential in enhancing independence, particularly in self-catheterization, the impact on overall HRQoL is not significantly different from the control group.
Allium roseum is amongst the most important wild medicinal plants. It is known for its diverse biological properties, including antioxidant, antibacterial and antidiabetic activities. In this work, the polysaccharides (PARLs) were ultrasonically extracted from Allium roesum leaves then purified and analyzed by several techniques. Chemical composition and GC-MS analysis showed that the obtained polysaccharides were composed mainly of glucose (40.20 %), mannose (25.30 %), fructose (10.60 %) and galacturonic acid (15.11 %). Moreover, PARLs exhibited a potent antioxidant effect with higher capacities up to 69.61 % and 71.72 % for DPPH and ABTS free radicals, respectively. Furthermore, PARLs significantly modulated inflammatory response by reducing TNF-α, IL-6, and IL-8 pro-inflammatory mediators and promoting the anti-inflammatory IL-10 mediator in LPS stimulated THP-1 derived macrophages. The in-vivo tests proved that the extract was able to decrease carrageenan-induced rat paw swelling by around 68.15 % after 4 h of treatment. PARLs, significantly reduced the growth of U87 (glioblastoma) and IGROV-1 cancer cells with IC50 values of about 4.27 and 7.89 mg/mL respectively. This research clearly shows that Allium roseum polysaccharides can be used as natural antioxidants with anti-inflammatory and anticancer properties.
Hypertrophic cardiomyopathy (HCM) is the most prevalent genetically inherited cardiovascular disorder in adults and a significant cause of heart failure and sudden cardiac death. Historically, atrial fibrillation (AF) has been considered as a critical aspect in HCM patients as it is considered to be a marker of disease progression, escalates the frequency of heart failure hospitalisations, increases the risk of thromboembolic events, and worsens quality of life and outcome. Increasing evidence suggests that AF is the result of a subtle long-standing process that starts early in the history of HCM. The process of left atrial dilation accompanied by morphologic and functional remodelling is the quintessential prerequisite for the onset of AF. This review aims to describe the current understanding of AF pathophysiology in HCM, emphasising the role of left atrial myopathy in its development. In addition, we discuss risk factors and management strategies specific to AF in the context of HCM, providing insights into the complexities and challenges of treating this specific patient population.
The invention relates to a medicine composition for treating sequelae of a pelvic inflammatory disease, a preparation method and application thereof. The medicine composition is prepared from the following Chinese medicinal herbs: astragalus membranaceus, dragon's blood, cassia twig, Chinese herbaceous peony, angelica sinensis, sargent gloryvine, herba portulaca, patrinia, dandelion, cooked rhubarb, the root bark of the peony tree, peach seed, myrrh, poria cocos and honey-fried licorice root. The medicine composition is prepared by adopting the steps of extracting an essential oil, decocting, concentrating, clarifying and drying. The preparation method is convenient to prepare, simple in conditions and safe and reliable. The medicine composition is applied to a medicine with the functions of invigorating the spleen and supplementing the qi, clearing heat and promoting diuresis, and dispersing blood stasis and removing dampness, and a medicine for treating the sequelae of the pelvic inflammatory disease. The medicine composition has a good clinical treatment effect, has the functions of benefiting qi and nourishing blood, warming channels and dispersing blood stasis, and benefiting the dampness and removing toxins, and accords with the characteristics of symptoms of deficiency, stasis, cold and dampness of the sequelae of the pelvic inflammatory disease. The medicine composition has the functions of remarkably improving the blood circulation of a patient, and improving the immunologic function and resisting the oxidation.
A biologically active hypotensive substance which is a colourless glittering crystalline solid having an acicular and prism-like structure, a melting-point between 153 DEG  and 155 DEG  C., [a ]21D in acetone of +367 DEG , [a ]21D in chloroform of +369 DEG , and an absorption spectrum in absolute ethyl alcohol with maxima at 225 and 317 mm , is extracted from plants of the oleaceae family, e.g. olea europa, olives.  Selected parts of the plants, e.g. bark, leaves, roots or fruits, or an extract of these parts in water or a water-miscible organic solvent, e.g. ethanol, acetone, are extracted with a non-water-miscible organic solvent, e.g. chloroform, methylene chloride, carbon tetrachloride and benzene, evaporating the separated non-water-miscible organic solvent, distilling the oily residue, if desired after a further purification, in vacuo and separating the fraction distilling between 120 DEG  and 160 DEG  C. at 0.1 mm. mercury and bringing this fraction to crystallization.  The extract of the plants in water or a water-miscible organic solvent may be subjected to an acid hydrolysis using an organic aliphatic acid, e.g. acetic, butyric, succinic or citric acid, or an inorganic acid, e.g. phosphoric, hydrochloric or sulphuric acid, or a cation exchanger in the acid form, e.g. Dowex-50.  The extract in the non-water-miscible organic solvent may be purified by evaporation, extracting the oily residue with water, extracting the filtered separated aqueous solution with ether and evaporating the ethereal extract and distilling the oily residue in vacuo as before.  The hypotensive substance may be administered orally or parenterally as tablets, solutions, suspensions or isotonic aqueous solutions, in admixture with normal excipients, e.g. gelatin, starch, lactose, cane sugar, talcum powder, stearic acid, magnesium stearate and physiological salt solutions.
In the dose escalation part of Stage I, five dose levels will be tested according to the "3 + 3" dose-escalation design. Whether and how to carry out the follow-up study parts will be decided by the PI and sponsor on the basis of the achieved results of safety, tolerability and effectiveness of CSPCHA131.